2 results
Approved WMORecruiting
Phase 1: • To determine the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors, including ALK+ IMT.• To characterize the PK of brigatinib administered as monotherapy in…
Approved WMORecruiting
The primary objective is to assess the effect of ICU-VR, offered early (within two weeks after ICU discharge) or late (three months after ICU discharge during an ICU follow-up clinic), on the severity of PTSD-related symptoms six months after ICU…